{"date":"2026-10-07","count":10,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-4175-2026-10-07-2347-9rfqim","company_id":"4175","company":"杏一","market":"上櫃","industry":"生技醫療","date":"2026-10-07","time":"23:47:36","subject":"本公司接獲消費者反映疑似個資外洩事件","clause":"第26款","fact_date":"2026-10-07","cite_as":"公開資訊觀測站重大訊息：杏一（4175），2026-10-07 23:47，「本公司接獲消費者反映疑似個資外洩事件」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7827-2026-10-07-2138-1s3mge2","company_id":"7827","company":"漢康-KY創","market":"上市","industry":"生技醫療","date":"2026-10-07","time":"21:38:05","subject":"代子公司FBD Biologics Limited公告，公司向TFDA提出HCB303新藥臨床試驗（IND）申請","clause":"第10款","fact_date":"2026-10-07","cite_as":"公開資訊觀測站重大訊息：漢康-KY創（7827），2026-10-07 21:38，「代子公司FBD Biologics Limited公告，公司向TFDA提出HCB303新藥臨床試驗（IND）申請」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7754-2026-10-07-1800-1uhskx3","company_id":"7754","company":"安基生技","market":"興櫃","industry":"生技醫療","date":"2026-10-07","time":"18:00:59","subject":"公告本公司董事會決議辦理現金增資發行新股","clause":"第9款","fact_date":"2026-10-07","cite_as":"公開資訊觀測站重大訊息：安基生技（7754），2026-10-07 18:00，「公告本公司董事會決議辦理現金增資發行新股」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7827-2026-10-07-1752-xhjfpb","company_id":"7827","company":"漢康-KY創","market":"上市","industry":"生技醫療","date":"2026-10-07","time":"17:52:41","subject":"公告本公司申請股票創新板初次第一上市時所出具之承諾事項暨其後續執行情形","clause":"第51款","fact_date":"2026-10-07","cite_as":"公開資訊觀測站重大訊息：漢康-KY創（7827），2026-10-07 17:52，「公告本公司申請股票創新板初次第一上市時所出具之承諾事項暨其後續執行情形」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-3164-2026-10-07-1641-ac89kl","company_id":"3164","company":"景岳","market":"上市","industry":"生技醫療","date":"2026-10-07","time":"16:41:36","subject":"公告本公司申請股票上櫃轉上市時所出具之承諾事項暨其後續執行情形","clause":"第51款","fact_date":"2026-10-07","cite_as":"公開資訊觀測站重大訊息：景岳（3164），2026-10-07 16:41，「公告本公司申請股票上櫃轉上市時所出具之承諾事項暨其後續執行情形」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7876-2026-10-07-1531-tznucr","company_id":"7876","company":"鼎晉生技","market":"興櫃","industry":"生技醫療","date":"2026-10-07","time":"15:31:14","subject":"公告本公司現金增資認股基準日等相關事宜(含原股東認購比例、代收股款及存儲專戶行庫)","clause":"第9款","fact_date":"2026-10-07","cite_as":"公開資訊觀測站重大訊息：鼎晉生技（7876），2026-10-07 15:31，「公告本公司現金增資認股基準日等相關事宜(含原股東認購比例、代收股款及存儲專戶行庫)」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7607-2026-10-07-1505-2s7ss0","company_id":"7607","company":"通用幹細胞*","market":"興櫃","industry":"生技醫療","date":"2026-10-07","time":"15:05:03","subject":"公告本公司董事會決議召開115年第二次股東臨時會(更正)","clause":"第32款","fact_date":"2026-09-17","cite_as":"公開資訊觀測站重大訊息：通用幹細胞*（7607），2026-10-07 15:05，「公告本公司董事會決議召開115年第二次股東臨時會(更正)」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6610-2026-10-07-1120-1fqkmsr","company_id":"6610","company":"安成生技","market":"興櫃","industry":"生技醫療","date":"2026-10-07","time":"11:20:03","subject":"澄清媒體報導","clause":"第26款","fact_date":"2026-10-07","cite_as":"公開資訊觀測站重大訊息：安成生技（6610），2026-10-07 11:20，「澄清媒體報導」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7759-2026-10-07-1045-1fqkmsr","company_id":"7759","company":"視航生醫","market":"興櫃","industry":"生技醫療","date":"2026-10-07","time":"10:45:09","subject":"澄清媒體報導","clause":"第26款","fact_date":"2026-10-07","cite_as":"公開資訊觀測站重大訊息：視航生醫（7759），2026-10-07 10:45，「澄清媒體報導」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6589-2026-10-07-0006-5r5yw5","company_id":"6589","company":"台康生技","market":"上市","industry":"生技醫療","date":"2026-10-07","time":"00:06:58","subject":"本公司向歐盟藥品管理局(EMA)提交生物相似藥EG1206A(Pertuzumab Biosimilar)液體注射劑420毫克產品之上市許可申請","clause":"第10款","fact_date":"2026-10-06","cite_as":"公開資訊觀測站重大訊息：台康生技（6589），2026-10-07 00:06，「本公司向歐盟藥品管理局(EMA)提交生物相似藥EG1206A(Pertuzumab Biosimilar)液體注射劑42」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}